Merit Medical Systems, Inc. Q2 2025 Earnings Recap

MMSI Q2 2025 August 1, 2025

Get alerts when MMSI reports next quarter

Merit Medical Systems reported strong Q2 2025 results with 13% year-over-year revenue growth and record-high non-GAAP operating margins, highlighting robust execution despite macroeconomic challenges.

Earnings Per Share Beat

$1.01 vs $0.86 est.

+17.4% surprise

Revenue Beat

382462000 vs 371452760 est.

+3.0% surprise

Market Reaction

1-Day +0.71%

5-Day +0.94%

30-Day +6.79%

See MMSI alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue reached $382.5 million, surpassing growth expectations with a 12.5% constant currency increase.
Non-GAAP operating margin improved to 21.2%, the highest in the company's public history, alongside a 10% increase in non-GAAP EPS.
Free cash flow rose by 20% year-over-year, amounting to $70 million, showcasing operational efficiency.
The strategic acquisition of Biolife Delaware for $120 million aims to enhance Merit's hemostatic product offerings, targeting a $350 million global market.
Martha Aronson was appointed as the new President and CEO, set to commence in October 2025, reinforcing the leadership transition strategy.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MMSI on AllInvestView.

Next Q1 2026